Back

Clinical trial updates

31 August 2019 (15:55 - 16:15)
Organised by:
Congress Presentation Part of: Targeting of PCSK9 with siRNA for LDL-C reduction in a high-risk population Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Christie Ballantyne

Baylor College of Medicine, Houston (United States of America)

4 More presentations in this session

Presentation thumbnail
Clinical implications for patients at persistent ASCVD risk
Doctor J. Saseen (Aurora, US)
Slides Video
Presentation thumbnail
The future of lipid management: new therapies for LDL-C lowering
Doctor H. Bays (Louisville, US)
Slides Video
Presentation thumbnail
Post-activity quiz and discussion
Doctor P. MORRIS (Charleston, US)
Slides Video
Presentation thumbnail
Questions and answers / Panel discussion
Slides Video

Access the full session

Session thumbnail
Targeting of PCSK9 with siRNA for LDL-C reduction in a high-risk population

The Event

Event poster

ESC Congress 2019

31 August 2019 15:55 CET
You may be interested in
thumbnail
Congress Presentation
Dyslipidaemias
26 August 2023
thumbnail
Congress Presentation
Active-target liposomal drug shows significant atherosclerotic plaque regression effect: a proof-of-concept phase 1b/2a clinical trial
1 September 2025
thumbnail
Congress Presentation
Triglyceride lowering after MI
1 September 2025
thumbnail
ESC TV Today
Episode 17: Coronary sinus reducer - Best strategies to reach LDL cholesterol goals
5 June 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources